[Chung Chan-seung] The collapse of trust: South Korea's true health care crisis
[KH Explains] Why doctors refuse to bend despite lack of public support
[KH Explains] What does Apple's dead car project mean for Samsung, Hyundai?
Actor Lee Jae-wook vows legal action against malicious rumors
Yoon, Zuckerberg discuss AI, digital ecosystem in Seoul
Police raid striking doctors' homes, offices, after deadline passes on return-to-work order
Interior minister renews calls for trainee doctors to return to work
Bitcoin soars to record high in Korea
Yoon touts improved Japan ties on Independence Movement Day as gateway to 'new world'
S. Korea, US voice 'deep concern' over NK's definition of S. Korea as 'hostile' country
Celltrion's Remsima SC lands in S. KoreaBy Yonhap
Published : Feb. 8, 2021 - 11:11
The subcutaneous (SC) version of Remsima, a biosimilar copy of Janssen Biotech Inc.'s Remicade, will hit the shelves domestically following approval a year earlier.
Remsima, administered through intravascular injections, is used in the treatment of a number of diseases, from rheumatoid arthritis to Crohn's disease, Celltrion said.
The SC version allows patients to conveniently inject it by themselves, unlike the intravenous formulation that requires patients to visit hospitals.
The company said it intends to improve its competitiveness in the local autoimmune disease therapeutic agent market with the existing Remsima and Remsima SC.
Celltrion has already won approval for the sale of Remsima SC in Europe and applied for patents in over 90 countries, including the United States. (Yonhap)
Yoon touts improved Japan ties on Independence Movement Day
Bill to probe first lady fails to pass
Address by President Yoon Suk Yeol on the 105th March 1st Independence Movement Day